title: Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling.
abstract: Interleukin-6 (IL-6) is a critical regulator of the immune system and has been widely implicated in autoimmune disease. Here, we describe the discovery and characterization of olokizumab, a humanized antibody to IL-6. Data from structural biology, cell biology and primate pharmacology demonstrate the therapeutic potential of targeting IL-6 at "Site 3", blocking the interaction with the signaling co-receptor gp130.
authors.affiliation: UCB Pharma; Berkshire, UK.
authors.forename: Stevan
authors.initials: S
authors.lastname: Shaw
authors.affiliation: UCB Pharma; Berkshire, UK.
authors.forename: Tim
authors.initials: T
authors.lastname: Bourne
authors.affiliation: UCB Pharma; Berkshire, UK.
authors.forename: Chris
authors.initials: C
authors.lastname: Meier
authors.affiliation: UCB Pharma; Berkshire, UK.
authors.forename: Bruce
authors.initials: B
authors.lastname: Carrington
authors.affiliation: Institute for Systems Biology; Seattle, WA USA.
authors.forename: Rich
authors.initials: R
authors.lastname: Gelinas
authors.affiliation: UCB Pharma; Berkshire, UK.
authors.forename: Alistair
authors.initials: A
authors.lastname: Henry
authors.affiliation: UCB Pharma; Berkshire, UK.
authors.forename: Andrew
authors.initials: A
authors.lastname: Popplewell
authors.affiliation: UCB Pharma; Berkshire, UK.
authors.forename: Ralph
authors.initials: R
authors.lastname: Adams
authors.affiliation: UCB Pharma; Berkshire, UK.
authors.forename: Terry
authors.initials: T
authors.lastname: Baker
authors.affiliation: UCB Pharma; Berkshire, UK.
authors.forename: Steve
authors.initials: S
authors.lastname: Rapecki
authors.affiliation: UCB Pharma; Berkshire, UK.
authors.forename: Diane
authors.initials: D
authors.lastname: Marshall
authors.affiliation: UCB Pharma; Berkshire, UK.
authors.forename: Adrian
authors.initials: A
authors.lastname: Moore
authors.affiliation: UCB Pharma; Berkshire, UK.
authors.forename: Helen
authors.initials: H
authors.lastname: Neale
authors.affiliation: UCB Pharma; Berkshire, UK.
authors.forename: Alastair
authors.initials: A
authors.lastname: Lawson
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D057134:Antibodies, Neutralizing / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D000936:Antigen-Antibody Complex / Q000737:chemistry; D001169:Arthritis, Experimental / Q000276:immunology / Q000628:therapy; D001665:Binding Sites; D018360:Crystallography, X-Ray; D050822:Cytokine Receptor gp130 / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000276:immunology*; D005260:Female; D006801:Humans; D006825:Hybridomas / Q000276:immunology; D007140:Immunoglobulin Fab Fragments / Q000737:chemistry / Q000235:genetics / Q000276:immunology; D015850:Interleukin-6 / Q000737:chemistry / Q000276:immunology*; D008252:Macaca fascicularis; D008958:Models, Molecular; D008969:Molecular Sequence Data; D051381:Rats; D017386:Sequence Homology, Amino Acid; D000093242:Interleukin-6 Inhibitors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D057134:Antibodies, Neutralizing; D000936:Antigen-Antibody Complex; D050822:Cytokine Receptor gp130; D007140:Immunoglobulin Fab Fragments; D015850:Interleukin-6; D000093242:Interleukin-6 Inhibitors; C508600:IL6 protein, human; C000592400:olokizumab
keywords: IL-6; antibody; gp130; interleukin 6; neutralization; olokizumab; site 3; structure